The Latest Breaking News from FDA

"Stomach paralysis" linked to drugs like Ozempic has raised alarm. What do doctors make of the reports?

Neuralink receives approval from the FDA for human experiment trials as experimentation looms.

Postpartum depression affects as many as 1 in 7 women in the U.S., though there are just two treatments approved for it. Experts say the newest could be a game-changer — depending on its price tag.

With the advent of advanced medications and the increasing need for personalized treatments, the pharmaceutical industry looks well-poised for long-term growth. Therefore, it could be worth looking into three fundamentally sound pharma stocks, Pfizer (PFE), Sanofi (SNY), and GSK plc (GSK), that are offering significant value. Read more….

A policy that wasn't rooted solely in science is diminished, but certain barriers to blood donation still remain

Donald Trump's legal team has until 5:00 p.m. to respond to prosecutors' request for a protective order. The FDA has approved the first pill to treat postpartum depression.

Drugmaker Novo Nordisk focuses on Black lawmakers and opinion leaders to spread the message that obesity is a chronic disease — worth treating at a cost of $1,000 or more a month.

Here’s what we know about the second drug to ever be approved for the post-pregnancy condition

The monoclonal antibody drug prevents the lung infection that puts 58,000 to 80,000 young children in the hospital each year.

The Food and Drug Administration granted approval of the drug, Zurzuvae, for adults experiencing severe depression related to childbirth or pregnancy. The pill is taken once a day for 14 days.

Federal health officials have approved the first pill to specifically treat depression after childbirth